Evaluation of the ability of Miltefosine associated with topical GM-CSF in modulating the immune response of patients with cutaneous Leishmaniasis

dc.creatorPeixoto, Fábio de Carvalho
dc.creatorNascimento, Maurício
dc.creatorCosta, Rúbia
dc.creatorSilva, Juliana
dc.creatorRenard, Gaby
dc.creatorGuimarães, Luiz Henrique
dc.creatorPenna, Gerson Oliveira
dc.creatorBarral-Netto, Manoel
dc.creatorCarvalho, Lucas P.
dc.creatorMachado, Paulo Roberto Lima
dc.creatorCarvalho, Edgar M.
dc.date2020-08-10T15:50:08Z
dc.date2020-08-10T15:50:08Z
dc.date2020
dc.date.accessioned2023-09-26T21:33:59Z
dc.date.available2023-09-26T21:33:59Z
dc.identifierPEIXOTO, Fábio et al. Evaluation of the ability of Miltefosine associated with topical GM-CSF in modulating the immune response of patients with cutaneous Leishmaniasis. Journal of Immunology Research, [s.l], v. 2020, n. 2789859, p. 1-9, Aug. 2020.
dc.identifier2314-7156
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/42614
dc.identifier10.1155/2020/2789859
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8872837
dc.descriptionGerson Oliveira Penna - Fundação Oswaldo Cruz. Fiocruz Brasília. Brasília, DF, Brasil. Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta a informação no documento do vinculo com a unidade da Fiocruz Brasília.
dc.descriptionMinistério da Saúde e pelo Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).
dc.descriptionCutaneous leishmaniasis (CL) due to L. braziliensis is associated with an exaggerated inflammatory response and tissue damage. Miltefosine is more effective than pentavalent antimony (Sbv ) in the treatment of CL, and here, we evaluate the ability of Sbv , miltefosine, and GM-CSF administered intravenously, orally, or topically, respectively, to modify the immune response. Patients were treated with miltefosine plus GM-CSF, miltefosine plus placebo, or Sbv . Mononuclear cells were stimulated with soluble Leishmania antigen (SLA) on day 0 and day 15 of therapy, and cytokine levels were determined in supernatants by ELISA. The lymphocyte proliferation and oxidative burst were evaluated by flow cytometry, and the degree of infection and Leishmania killing by optical microscopy. Proliferation of CD4+ T cells were enhanced in patients using miltefosine and in CD8+ T cells when GM-CSF was associated. Enhancement in the oxidative burst occurred in the miltefosine plus GM-CSF group on day 15 of therapy. Moreover, the number of L. braziliensis in infected monocytes on day 15 as well as the percentage of infected cells was lower after 48- and 72-hour culture in cells from patients treated with miltefosine plus GM-CSF. In addition to the ability of miltefosine to kill Leishmania, the changes in the immune response caused by miltefosine and GM-CSF may increase the cure rate of CL patients using these drugs.
dc.formatapplication/pdf
dc.languageeng
dc.publisherHindawi
dc.rightsopen access
dc.subjectAdministration, Oral
dc.subjectAntiprotozoal Agents
dc.subjectClinical Trials as Topic
dc.subjectLeishmaniasis
dc.subjectCutaneous leishmaniasis
dc.subjectMiltefosine
dc.subjectLeishmaniose
dc.subjectLeishmaniose Cutânea
dc.subjectEnsaios Clínicos como Assunto
dc.subjectResultado do Tratamento
dc.titleEvaluation of the ability of Miltefosine associated with topical GM-CSF in modulating the immune response of patients with cutaneous Leishmaniasis
dc.typeArticle


Este ítem pertenece a la siguiente institución